These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 38594140)

  • 21. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality.
    Peña C; Gudiol C; Calatayud L; Tubau F; Domínguez MA; Pujol M; Ariza J; Gudiol F
    J Hosp Infect; 2008 Feb; 68(2):116-22. PubMed ID: 18226420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients.
    Jones RN
    Am J Med; 1996 Jun; 100(6A):3S-12S. PubMed ID: 8678095
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmid-mediated AmpC beta-lactamase-producing Escherichia coli causing urinary tract infection in the Auckland community likely to be resistant to commonly prescribed antimicrobials.
    Drinkovic D; Morris AJ; Dyet K; Bakker S; Heffernan H
    N Z Med J; 2015 Mar; 128(1410):50-9. PubMed ID: 25829039
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ceftazidime/avibactam: a novel cephalosporin/nonbeta-lactam beta-lactamase inhibitor for the treatment of complicated urinary tract infections and complicated intra-abdominal infections.
    Hidalgo JA; Vinluan CM; Antony N
    Drug Des Devel Ther; 2016; 10():2379-86. PubMed ID: 27528799
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Aminoglycoside therapy for childhood urinary tract infection due to extended-spectrum β-lactamase-producing Escherichia coli or Klebsiella pneumoniae.
    Han SB; Lee SC; Lee SY; Jeong DC; Kang JH
    BMC Infect Dis; 2015 Oct; 15():414. PubMed ID: 26464143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Meropenem-vaborbactam for the treatment of complicated urinary tract infections including acute pyelonephritis.
    Wu G; Cheon E
    Expert Opin Pharmacother; 2018 Sep; 19(13):1495-1502. PubMed ID: 30160990
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli.
    Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K
    J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urinary tract infection caused by extended-spectrum β-lactamase-producing bacteria: Risk factors and antibiotic resistance.
    Albaramki JH; Abdelghani T; Dalaeen A; Khdair Ahmad F; Alassaf A; Odeh R; Akl K
    Pediatr Int; 2019 Nov; 61(11):1127-1132. PubMed ID: 31206219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase-producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis.
    Senard O; Lafaurie M; Lesprit P; Nguyen Y; Lescure X; Therby A; Fihman V; Oubaya N; Lepeule R
    Eur J Clin Microbiol Infect Dis; 2020 Jan; 39(1):121-129. PubMed ID: 31512147
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Does urinary tract infection caused by extended-spectrum β-lactamase-producing Escherichia coli show same antibiotic resistance when it recurs?
    Ahn ST; Kim SW; Kim JW; Park HS; Moon DG; Oh MM
    J Infect Chemother; 2019 Jul; 25(7):498-502. PubMed ID: 30852104
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment and Outcomes of Children With Febrile Urinary Tract Infection Due to Extended Spectrum Beta-lactamase-producing Bacteria in Europe: TOO CUTE Study.
    Vazouras K; Hsia Y; Folgori L; Bielicki J; Aguadisch E; Bamford A; Brett A; Caseris M; Cerkauskiene R; De Luca M; Iosifidis E; Kopsidas J; Manzanares Á; Planche T; Riordan A; Srovin TP; Valdivielso Martínez AI; Vergadi E; Sharland M; Basmaci R
    Pediatr Infect Dis J; 2020 Dec; 39(12):1081-1087. PubMed ID: 32947600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Non-carbapenem antimicrobial therapy in young infant with urinary tract infections caused by community-acquired extended-spectrum β-lactamase-producing Escherichia coli.
    Jo KJ; Yoo S; Song JY; Kim SH; Park SE
    Pediatr Neonatol; 2021 May; 62(3):271-277. PubMed ID: 33602619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of community-onset healthcare-associated and hospital-acquired urinary infections caused by extended-spectrum beta-lactamase-producing Escherichia coli and antimicrobial activities.
    Saltoglu N; Karali R; Yemisen M; Ozaras R; Balkan II; Mete B; Tabak F; Mert A; Hondur N; Ozturk R
    Int J Clin Pract; 2015 Jul; 69(7):766-70. PubMed ID: 25683907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-carbapenem β-lactam/β-lactamase inhibitors versus carbapenems for urinary tract infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: a systematic review.
    Zhang H; Liang B; Wang J; Cai Y
    Int J Antimicrob Agents; 2021 Oct; 58(4):106410. PubMed ID: 34339776
    [TBL] [Abstract][Full Text] [Related]  

  • 35. What is the role of the new β-lactam/β-lactamase inhibitors ceftolozane/tazobactam and ceftazidime/avibactam?
    Gentile I; Maraolo AE; Borgia G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):875-8. PubMed ID: 27599088
    [No Abstract]   [Full Text] [Related]  

  • 36. AAUS guideline for acute uncomplicated pyelonephritis.
    Shigemura K; Ishikawa K
    J Infect Chemother; 2022 Aug; 28(8):1092-1097. PubMed ID: 35613961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
    Delory T; Gravier S; Le Pluart D; Gaube G; Simeon S; Davido B; Piet E; Lepeule R; Lesprit P; Lafaurie M
    Int J Antimicrob Agents; 2021 Jul; 58(1):106361. PubMed ID: 34000372
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Urinary tract infection caused by community-acquired extended-spectrum β-lactamase-producing bacteria in infants.
    Kim YH; Yang EM; Kim CJ
    J Pediatr (Rio J); 2017; 93(3):260-266. PubMed ID: 27842212
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extended spectrum beta lactamase producing organisms causing urinary tract infections in Sri Lanka and their antibiotic susceptibility pattern -A hospital based cross sectional study.
    Fernando MM; Luke WA; Miththinda JK; Wickramasinghe RD; Sebastiampillai BS; Gunathilake MP; Silva FH; Premaratna R
    BMC Infect Dis; 2017 Feb; 17(1):138. PubMed ID: 28187754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
    D'Angelo RG; Johnson JK; Bork JT; Heil EL
    Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.